THE 2026 CALIBRATE RESULTS REPORT
Maximizing the Clinical and Economic Value of GLP-1 Therapy
For benefits leaders, total rewards teams, brokers, consultants, and health-plan partners need, this report delivers the evidence base to ensure your GLP-1 coverage is driving the outcomes you're paying for.
Download 2026 Results Report
Sustained Weight Loss Over 4 Years
Members keep losing weight, with significant results observed at 4 years
Biggest Impact in Highest-Risk Members
Class II & III Obesity members lose more over time
Metabolic Health Improvement Beyond Weight
80% normalized abnormal HbA1c, 72% normalized insulin, and more
Consistent Results Across Workforces
Results hold across industries, from sedentary, high-stress roles to high-physicality jobs